Matsuda and collaborators successfully imaged PSMA expression in three patients followed for recurrent high-grade gliomas and brain metastases using 89Zr-Df-IAB2M anti-PSMA minibody and outlined a trend for the binding intensity of this tracer to correlate with PSMA expression level in tumor vessels. This evidence concerns the gene FOLH1 and central nervous system cancer.